

## 11

7-nitroindazole, S-ethylisothiurea, S-methylisothiurea, S-methylthiocitriulline, S-ethylthiocitrulline, N-ethylimino-L-ornithine, flavoprotein binders, diphenyleneiodonium and related iodonium derivatives, ornithine and ornithine derivatives; tetracycline and derivatives; L-canavanine; citrulline; redox dyes, methylene blue; calmodulin binders, trifluoropiperazine and calcein, heme binders; resveratrol; zinc compounds; tetrahydropterin analogs, aminoguanidine, and depleters of biopterin, methotrexate, nonsteroidal anti-inflammatory agents, sodium salicylate, nitric oxide scavengers and mixtures thereof.

3. The composition of claim 1, wherein said aminosugar is selected from the group consisting of: glucosamine, glucosamine hydrochloride, glucosamine sulfate, N-acetylglucosamine and mixtures thereof.

4. The composition of claim 1, which optionally contains additional agents selected from the group consisting of: glycosaminoglycans; vitamin A, vitamin B, vitamin C, vitamin E and derivatives thereof; selenium, silica, manganese, magnesium, copper, boron, analgesics, anti-inflammatory agents, enzymes, methyl-sulfonyl-methane, S-adenosyl-methionine, alpha-lipoic acid, aloe vera extract, antioxidants, anti-infective agents, collagen type II, adjuvants, anthocyanidins, proanthocyanidins, and herbal derivatives, and mixtures thereof.

5. The method of claim 1, optionally contains a controlled release method of an enteric coating to deliver the composition orally into the gastrointestinal tract.

6. The composition of claim 1, which further comprises of a pharmaceutically acceptable carrier suitable for oral, rectal, parenteral, intravenous, topical, transdermal, subcutaneous and intramuscular administration.

7. A method for treating arthritis in mammals by administering a therapeutically effective amount of a composition comprising:

- a) an inhibitor of nitric oxide production, and
- b) an aminosugar.

8. The composition of claim 7, wherein said inhibitors of nitric oxide production comprises nitric oxide synthase inhibitors comprising; arginine-based analogues, methylated

## 12

arginines, substituted L-arginine, nitro-arginine, L-N<sup>G</sup>-nitroarginine, N<sup>G</sup>-mono-methyl-L-arginine (L-NMMA), N-nitro-L-arginine methyl ester (L-NAME), N-amino-L-arginine, N-methyl-L-arginine, N<sup>G</sup>-monomethyl-L-arginine (L-NMA), N<sup>G</sup>-nitro-L-arginine (L-NNA), aminoguanidine, 7-nitroindazole, S-ethylisothiurea, S-methylisothiurea, S-methylthiocitriulline, S-ethylthiocitrulline, N-ethylimino-L-ornithine, flavoprotein binders, diphenyleneiodonium and related iodonium derivatives, ornithine and ornithine derivatives; tetracycline; L-canavanine; citrulline; redox dyes, methylene blue; calmodulin binders, trifluoropiperazine and calcein, heme binders; resveratrol; zinc compounds; tetrahydropterin analogs, aminoguanidine, and depleters of biopterin, methotrexate, nonsteroidal anti-inflammatory agents, sodium salicylate, nitric oxide scavengers and mixtures thereof.

9. The method of claim 7, wherein said aminosugar in the composition is selected from the group consisting of: glucosamine, glucosamine hydrochloride, glucosamine sulfate, N-acetylglucosamine and mixtures thereof.

10. The method of claim 7, wherein the composition optionally contains additional L agents selected from the group consisting of: glycosaminoglycans; vitamin A, vitamin B, vitamin C, vitamin E and derivatives thereof; selenium, silica, manganese, magnesium, copper, boron, analgesics, anti-inflammatory agents, enzymes, methyl-sulfonyl-methane, S-adenosyl-methionine, alpha-lipoic acid, aloe vera extract, antioxidants, anti-infective agents, collagen type II, adjuvants, anthocyanidins, proanthocyanidins, and herbal derivatives, and mixtures thereof.

11. The method of claim 7, optionally a controlled release method of an enteric coating to deliver the composition orally into the gastrointestinal tract.

12. The method of claim 7, which further comprises of a pharmaceutically acceptable carrier suitable for oral, rectal, parenteral, intravenous, topical, transdermal, subcutaneous and intramuscular administration.

\* \* \* \* \*